Conclusions: Our results suggest that vaccines other than influenza vaccine can be associated with GBS. Vaccination-related GBS results in death or disability in one fifth of affected individuals, which is comparable to the reported rates in the general GBS population
http://journals.lww.com/jcnmd/Abstract/2009/09000/Guillain_Barre_Syndrome_after_Vaccination_in.1.aspx
Autoimmune reactions to vaccinations may rarely be induced in predisposed individuals by molecular mimicry or bystander activation mechanisms. Autoimmune reactions reliably considered vaccine-associated, include Guillain-Barré syndrome after 1976 swine influenza vaccine, immune thrombocytopenic purpura after measles/mumps/rubella vaccine, and myopericarditis after smallpox vaccination, whereas the suspected association between hepatitis B vaccine and multiple sclerosis has not been further confirmed, even though it has been recently reconsidered, and the one between childhood immunization and type 1 diabetes seems by now to be definitively gone down. Larger epidemiological studies are needed to obtain more reliable data in most suggested associations.
Read More:
http://informahealthcare.com/doi/abs/10.3109/08830181003746304
Vaccines, in several reports were found to be temporally followed by a new onset of autoimmune diseases. The same mechanisms that act in infectious invasion of the host, apply equally to the host response to vaccination. It has been accepted for diphtheria and tetanus toxoid, polio and measles vaccines and GBS. Also this theory has been accepted for MMR vaccination and development of autoimmune thrombocytopenia, MS has been associated with HBV vaccination.
Read More:
http://informahealthcare.com/doi/abs/10.1080/08916930500050277
Hepatitis B infection is one of the most important causes of acute and chronic liver disease. During the 1980s, genetically engineered hepatitis B vaccines (HBVs) were introduced in the United States. A large-series of serious autoimmune conditions have been reported following HBVs, despite the fact that HBVs have been reported to be “generally well-tolerated.” A case-control epidemiological study was conducted to evaluate serious autoimmune adverse events prospectively reported to the vaccine adverse events reporting system (VAERS) database following HBVs, in comparison to an age, sex, and vaccine year matched unexposed tetanus-containing vaccine (TCV) group for conditions that have been previously identified on an a priori basis from case-reports. Adults receiving HBV had significantly increased odds ratios (OR) for multiple sclerosis (OR = 5.2, p < 0.0003, 95% Confidence Interval (CI) = 1.9 – 20), optic neuritis (OR = 14, p < 0.0002, 95% CI = 2.3 – 560), vasculitis (OR = 2.6, p < 0.04, 95% CI = 1.03 – 8.7), arthritis (OR = 2.01, p < 0.0003, 95% CI = 1.3 – 3.1), alopecia (OR = 7.2, p < 0.0001, 95% CI = 3.2 – 20), lupus erythematosus (OR = 9.1, p < 0.0001, 95% CI = 2.3 – 76), rheumatoid arthritis (OR = 18, p < 0.0001, 95% CI = 3.1 – 740), and thrombocytopenia (OR = 2.3, p < 0.04, 95% CI = 1.02 – 6.2) in comparison to the TCV group. Minimal confounding or systematic error was observed. Despite the negative findings of the present study regarding the rare serious adverse effects of HBVs, it is clear that HBV does, indeed, offer significant benefits, but it is also clear that chances of exposure to hepatitis B virus in adults is largely life-style dependent. Adults should make an informed consent decision, weighing the risks and benefits of HBV, as to whether or not to be immunized
http://www.ncbi.nlm.nih.gov/pubmed/16206512
HBV was associated with a number of serious conditions and positive re-challenge or significant exacerbation of symptoms following immunization.